ReviewBriefings in bioinformatics2026
Multimodal foundation models in colorectal cancer: from prediction to trustworthy clinical insight.
Review in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is characterized by profound, multi-layered heterogeneity that limits the precision of conventional single-modality clinical tools. The emergence of multimodal foundation models (MFMs) represents a conceptual paradigm shift, moving beyond static biomarkers to capture the dynamic and evolving nature of CRC. MFMs integrate histopathology, radiology, multi-omics data (including the critical regulatory layer of epigenomics), and clinical variables into shared high-dimensional representational spaces. This integration enables improved prognostication, refined molecular subtyping, and in silico simulation of therapeutic perturbations within the tumor's functional landscape, thereby supporting rational and model-driven drug development. In this review, we synthesize the rapidly expanding body of CRC-specific MFM research and critically examine the unresolved challenges that currently limit clinical translation. We place particular emphasis on the transition from correlation to causal inference, the establishment of cross-population generalizability, and the resolution of key issues related to trustworthiness and clinical interpretability. Finally, we propose an actionable roadmap outlining regulatory, data governance, and translational requirements, including the lab-in-the-loop paradigm, necessary to position MFMs as a robust and equitable framework in clinical oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.